Clinical application
Early-stage lung cancer auxiliary screening.
Lung nodule risk-stratification reference indicator.
Complement CT imaging assessment with an immunological dimension.
Principle
The seven lung cancer-associated autoantibodies kit detects 7 targets at the same time:
p53, GAGE7, PGP9.5, CAGE, MAGE A1, SOX2 and GBU4-5.
This assay detects autoantibodies against seven lung-cancer-associated antigens. The invasive or indolent tendency of tumor biological activity reflected by tumor immuneresponse signals, thereby indicating the possibility of tumor malignant transformation.
Highlights
Validated biomarker: Only prospectively validated lung cancer screening biomarker
High specificity: About 90% specificity with 7 autoantibody panel
High stability: Longer half-life of antibodies than antigens ensures stable detection
Non-invasive & Convenient: Only requires a blood sample
Fully automated: Chemiluminescence technology, results in about 30 minutes
Specification
| Specification: | 100 Test/Kit |
| Sample type: | Human serum |
| Sample volume: | 70 μL |
| Test time: | 30 mins |
| Storage conditions: | 2–8°C |
| Shelf life: | 12 months |
| Certification: | CE |
